



G1 Therapeutics to Host Virtual R&D Day on September 15, 2022

September 6, 2022

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: [GTHX](#)), a commercial-stage oncology company, today announced that the Company will host a virtual R&D Day, "Innovations in Oncology: The Science of Trilaciclib", on Thursday, September 15, 2022, from 9:00 a.m. to 11:00 a.m. ET.

G1 will review the development and expansion strategy for trilaciclib, its innovative investigational therapy to improve the lives and outcomes of people living with cancer. The Company will also present new preclinical data supporting potential of trilaciclib to work synergistically with other anti-cancer therapies. Trilaciclib is currently in clinical trials assessing its myeloprotective and anti-tumor immunomodulatory effects in a range of tumor types and in combination with a variety of treatments, including ADCs and checkpoint inhibitors.

Additionally, the program will feature insights from leading clinicians on the differentiated and broadly applicable immune-based mechanism of action of trilaciclib; the importance of transient CDK4/6 inhibition; and the urgent need to improve treatment options for patients with colorectal cancer:

- Shom Goel, B Med Sci, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, The University of Melbourne
- Richard Goldberg, MD, Professor Emeritus and former Director, West Virginia University Cancer Institute (WVUCI)

A webcast of the event can be accessed on the [Events & Presentations](#) page of www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.

About G1 Therapeutics

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics™ and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to trilaciclib's potential to work synergistically with other anti-cancer therapies. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the company's dependence on the commercial success of COSELA; the development and commercialization of new drug products is highly competitive; the company's ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the company's initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; and market conditions. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

Rebecca Levine
Director, Corporate Communications and Public Relations
919-667-8711
rlevine@g1therapeutics.com



Source: G1 Therapeutics